论文部分内容阅读
用高效液相色谱法测定人血中Vc,对10名健康志愿者po Vc Na胶囊的相对生物利用度及其药物动力学进行研究.结果受试药Vc Na胶囊和对照药Vc片的C_(max)为(67.71±24.13)和(74.33±17.50)μmol/L;T_(1/2)为(7.44±2.00)和(7.69±3.07)h;AUC为(746.4±411.4)和(785.4±428.8)μmol·h/L.各参数经配对t检验均无显著性差异,显示两种制剂体内吸收、分布和消除基本一致.Vc-Na胶囊人体相对生物利用度为(95.1±9.1)%.提示Vc Na胶囊可作为Vc在临床上应用.
The relative bioavailability and pharmacokinetics of po Vc Na capsule in 10 healthy volunteers were determined by HPLC.Results The Vc of the Vc Na capsule and the control drug Vc max was 67.71 ± 24.13 and 74.33 ± 17.50 μmol / L respectively; T 1/2 was 7.44 ± 2.00 and 7.69 ± 3.07 h; AUC was (746.4 ± 411.4) and (785.4 ± 428.8), respectively ) μmol · h / L.There was no significant difference in paired t test between the two parameters, which showed that the absorption, distribution and elimination of the two preparations were basically consistent.The relative bioavailability of VC-Na capsule was (95.1 ± 9.1)%. Vc Na capsule can be used clinically as Vc.